Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK, RSV and Shingles
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older. The British pharma giant said Wednesday a Phase 3 study evaluating RSV vaccine Arexvy co-administered with Shingrix met the primary endpoint,
2d
GSK falls Friday, underperforms market
GSK PLC GSK shares slipped 2.45% to £15.36 Friday, on what proved to be an all-around grim trading session for the stock ...
5h
on MSN
Down another 6% in a week! So will the GSK share price ever recover?
The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...
4d
GSK settles two California lawsuits related to heartburn drug Zantac
British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued ...
news.stocktradersdaily
2d
Trading (GSK) With Integrated Risk Controls
GET MORE AI-GENERATED SIGNALS: September 19, 2024, 20:16 pm ET, BY Jeff W.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...
BioSpace
6d
GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC
High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...
8d
GSK, iTeos Lung Cancer Data Set to Reignite Hope for Drug Class
Early data from GSK Plc and iTeos Therapeutics’ mid-stage trial of a lung cancer medicine looks set to renew cautious ...
STAT
8d
Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target
A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising ...
3d
Boehringer, GSK, Pfizer Still Face Zantac Cases Despite Mistrial
An Illinois mistrial involving the recalled medication Zantac is the latest court decision involving the recalled drug, but ...
FiercePharma
4d
AstraZeneca's Fasenra plays catch-up with GSK's Nucala, gaining FDA nod for rare autoimmune disease
Since
GSK
’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients with severe asthma, the IL-5 ...
5d
GSK falls Tuesday, underperforms market
Shares of GSK PLC GSK dropped 1.38% to £16.10 Tuesday, on what proved to be an all-around favorable trading session for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback